Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Sector news Biotechnology & Medical Research - NEC
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
08/29DJWHAT'S NEWS : Business & Finance -- WSJ
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- 2nd Update
08/28DJGILEAD SCIENCES : The Promising New Cancer Treatment Behind Gilead's $11 Billion..
08/28DJHot Stocks to Watch in the U.S. and Canada
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion -- Update
08/28DJGILEAD SCIENCES : to Buy Kite Pharma for Roughly $11 Billion in Cash
08/25 Samsung, Biogen version of AbbVie's Humira approved in Europe
08/24 Cyclicals boost European shares while Dixons Carphone plummets
08/17 FDA expands use of AstraZeneca/Merck ovarian cancer drug
08/15 Three CEOs resign from Trump council over Charlottesville
08/14DJHot Stocks to Watch in the U.S. and Canada
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/11DJGILEAD SCIENCES : England's NHS Turns to Clinical Trial to Make Cheaper HIV Drug..
08/10 Cyclicals and ex-divs send European shares to four-month low
07/31 France's Sanofi raises earnings forecast, pleased with eczema drug uptake
07/31DJSanofi 2Q Net Profit Down 10% at EUR1.04 Billion
07/27DJUNITED THERAPEUTICS : in Settlement Talks With Justice Department -- Update
07/26 Autos and energy firms boost European shares as earnings roll in, banks held ..
07/25DJCELGENE : Settles Lawsuit Over Improper Promotion of Cancer Drugs
07/25DJELI LILLY AND : to Delay Arthritis Drug Application -- Market Talk
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/18 JOHNSON & JOHNSON : J&J sees sales growth in near-term; raises 2017 profit forec..
07/12 FDA panel backs Novartis' pioneering new cancer gene therapy
06/29 UK and industrials prominent in Goldman strategists' M&A target reshuffle
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/20 Novartis eye drug works with fewer injections than rival
06/15DJACTELION : J&J Maps Research Plans for Actelion -- WSJ
06/14DJACTELION : Correction to J&J Actelion Story
06/14DJACTELION : J&J Plans to Add Drug Discovery and Early Research to Actelion Unit
06/14 JOHNSON & JOHNSON : flu drug succeeds in mid-stage trial
06/09 ACTELION : Johnson & Johnson expects to complete Actelion purchase on June 16
06/09 ACTELION : Johnson & Johnson expects to complete of Actelion offer on June 16
06/02DJBluebird Bio stock jumps 7% after Maxim Group upgrades to buy -- MarketWatch
05/31 GILEAD SCIENCES : and GSK go head-to-head with similar HIV drug data
05/23 UK competition watchdog accuses Merck of obstructing biosimilars
05/22 Cross-border M&A between U.S. and European firms at 10 year high
05/22DJAMGEN : Another Gloomy Day for Amgen
05/09 Sanofi pegs U.S. drug price rises to below healthcare inflation
05/09DJVERTEX PHARMACEUTICALS INCORPORATED : Trump's Pick to Lead FDA Has Backing of Bi..
05/07 REGENERON SHARES POISED FOR REBOUND : Barron's
05/07 REGENERON PHARMACEUTICALS : shares poised for rebound - Barron's
05/02 JACK MA : Temasek, Yunfeng lead $75 million funding into China genomics firm
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
Financials ($)
Sales 2017 1,63 M
EBIT 2017 -120 M
Net income 2017 -97,2 M
Finance 2017 3,37 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 266x
EV / Sales 2018 135x
Capitalization 435 M
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalization (M$)
PURETECH HEALTH PLC14.32%435
INCYTE CORPORATION18.83%24 941
QUINTILES IMS HOLDINGS INC24.22%20 585
LONZA GROUP54.86%19 540
CELLTRION, INC.--.--%15 038
ALKERMES PLC-6.41%7 993
SEATTLE GENETICS, INC.1.93%7 565
QIAGEN NV10.01%7 412
IONIS PHARMACEUTICALS INC23.83%7 408
ALNYLAM PHARMACEUTICALS, INC.103.55%6 972
ICON PLC48.06%6 128
UNITED THERAPEUTICS CORPORATION-15.78%5 204
CHARLES RIVER LABORATORIES INTL. INC39.15%5 106
GALAPAGOS39.12%5 095
EXACT SCIENCES CORPORATION219.99%5 060
PRA HEALTH SCIENCES INC35.96%4 695
BIO-TECHNE CORP18.23%4 552
ACADIA PHARMACEUTICALS INC.28.22%4 526
PAREXEL INTERNATIONAL CORPORATION33.83%4 498
FIBROGEN INC144.86%4 166
PUMA BIOTECHNOLOGY INC233.06%3 905